医学
脉络膜新生血管
黄斑变性
眼科
疾病
人口
血管抑制剂
病态的
阿柏西普
验光服务
梅德林
光学相干断层摄影术
重症监护医学
作者
Chui Ming Gemmy Cheung,Jennifer J. Arnold,Frank G. Holz,Kyu Hyung Park,Timothy Y Y Lai,Michael Larsen,Paul Mitchell,Kyoko Ohno-Matsui,Shih-Jen Chen,Sebastian Wolf,Tien Yin Wong
出处
期刊:Ophthalmology
[Elsevier]
日期:2017-11-01
卷期号:124 (11): 1690-1711
被引量:71
标识
DOI:10.1016/j.ophtha.2017.04.028
摘要
Topic The aim of this article is to review and compile available information on the classification, pathophysiology, and clinical features of (CNV); to describe the latest data on the management of this disease; and to present guidance. Clinical Relevance In the United States, affects approximately 34 million people (2010), and similar figures have been reported in Europe. Pathologic (PM), a possible consequence of myopia, is estimated to affect up to 3% of the global population. One of the most serious complications of PM is CNV, which often leads to a sudden onset but progressive decline in central vision and is associated with a poor prognosis unless treated. Furthermore, 35% of patients with CNV develop bilateral disease in the fellow eye within 8 years. Although intravitreal anti–vascular endothelial growth factor (VEGF) therapies have had a major impact on the management of patients with CNV, there remain significant gaps in our understanding of this condition and how to best administer treatment. Additionally, the long-term safety and efficacy of these treatments are largely unknown. Methods We carried out a literature review (September 2015) of all English-language articles in PubMed resulting from searches of the following terms: choroidal neovascularization AND OR myopic macular degeneration OR degenerative myopia OR myopic maculopathy OR myopic retinopathy OR pathological myopia OR pathologic myopia. Results We screened a total of 566 abstracts, and 250 articles were deemed relevant for full publication review. We excluded a further 71, but an additional 44 articles were identified. This resulted in 223 articles being used to develop this review. Conclusions Highly patients experiencing a sudden loss of central vision should be referred for further examination. Once a diagnosis of CNV has been confirmed, after fluorescein angiography, treatment initiation should be prompt and anti-VEGF agents considered as first-line therapy, unless contraindicated. Continued monitoring of patients is required to assess any progression or recurrence of the condition.
科研通智能强力驱动
Strongly Powered by AbleSci AI